Clinical Trial Update: To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial comparing the GI safety of a 14-day oral regimen of ATB-346 to sodium naproxen in healthy subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Ulcer

Drugs mentioned

• ATB-346
• Sodium naproxen (naproxen sodium)

Snippet

Sponsor: Antibe Therapeutics Inc. | Conditions: Gastric Ulcer | Phase 1, Phase 2 | Status: COMPLETED